Candidate biomarkers for fatigue in systemic lupus erythematosus

A critical review

Mary Alison Mahieu*, Rosalind Ramsey-Goldman

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Fatigue impacts 80-90% of patients with systemic lupus erythematosus (SLE), and an incomplete understanding of fatigue mechanisms limits effective treatment. Disease activity indices and laboratory markers inconsistently correlate with fatigue severity in SLE populations. Identification of fatigue biomarkers has important implications for understanding pathogenesis and defining novel therapeutic targets, but a paucity of evidence exists for fatigue biomarkers in SLE. The evidence for adipokines, reduced glutathione, iron deficiency, and vitamin D as potential biomarkers for SLE-related fatigue are reviewed. To address gaps in the SLE literature, the experience of each fatigue biomarker in other diseases is examined. Finally, biomarker associations with SLE pathogenesis and disease activity are discussed, as further rationale for investigation among SLE patients.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalCurrent Rheumatology Reviews
Volume13
Issue number2
DOIs
StatePublished - Aug 1 2017

Fingerprint

Systemic Lupus Erythematosus
Fatigue
Biomarkers
Adipokines
Vitamin D Deficiency
Glutathione
Iron
Therapeutics
Population

Keywords

  • Adipokines
  • Biomarkers
  • Fatigue
  • Glutathione
  • Iron deficiency
  • Systemic lupus erythematosus
  • Vitamin D

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{dabca1b7d7734d4f903075da167ed21c,
title = "Candidate biomarkers for fatigue in systemic lupus erythematosus: A critical review",
abstract = "Fatigue impacts 80-90{\%} of patients with systemic lupus erythematosus (SLE), and an incomplete understanding of fatigue mechanisms limits effective treatment. Disease activity indices and laboratory markers inconsistently correlate with fatigue severity in SLE populations. Identification of fatigue biomarkers has important implications for understanding pathogenesis and defining novel therapeutic targets, but a paucity of evidence exists for fatigue biomarkers in SLE. The evidence for adipokines, reduced glutathione, iron deficiency, and vitamin D as potential biomarkers for SLE-related fatigue are reviewed. To address gaps in the SLE literature, the experience of each fatigue biomarker in other diseases is examined. Finally, biomarker associations with SLE pathogenesis and disease activity are discussed, as further rationale for investigation among SLE patients.",
keywords = "Adipokines, Biomarkers, Fatigue, Glutathione, Iron deficiency, Systemic lupus erythematosus, Vitamin D",
author = "Mahieu, {Mary Alison} and Rosalind Ramsey-Goldman",
year = "2017",
month = "8",
day = "1",
doi = "10.2174/1573397112666161029224953",
language = "English (US)",
volume = "13",
pages = "103--112",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

Candidate biomarkers for fatigue in systemic lupus erythematosus : A critical review. / Mahieu, Mary Alison; Ramsey-Goldman, Rosalind.

In: Current Rheumatology Reviews, Vol. 13, No. 2, 01.08.2017, p. 103-112.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Candidate biomarkers for fatigue in systemic lupus erythematosus

T2 - A critical review

AU - Mahieu, Mary Alison

AU - Ramsey-Goldman, Rosalind

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Fatigue impacts 80-90% of patients with systemic lupus erythematosus (SLE), and an incomplete understanding of fatigue mechanisms limits effective treatment. Disease activity indices and laboratory markers inconsistently correlate with fatigue severity in SLE populations. Identification of fatigue biomarkers has important implications for understanding pathogenesis and defining novel therapeutic targets, but a paucity of evidence exists for fatigue biomarkers in SLE. The evidence for adipokines, reduced glutathione, iron deficiency, and vitamin D as potential biomarkers for SLE-related fatigue are reviewed. To address gaps in the SLE literature, the experience of each fatigue biomarker in other diseases is examined. Finally, biomarker associations with SLE pathogenesis and disease activity are discussed, as further rationale for investigation among SLE patients.

AB - Fatigue impacts 80-90% of patients with systemic lupus erythematosus (SLE), and an incomplete understanding of fatigue mechanisms limits effective treatment. Disease activity indices and laboratory markers inconsistently correlate with fatigue severity in SLE populations. Identification of fatigue biomarkers has important implications for understanding pathogenesis and defining novel therapeutic targets, but a paucity of evidence exists for fatigue biomarkers in SLE. The evidence for adipokines, reduced glutathione, iron deficiency, and vitamin D as potential biomarkers for SLE-related fatigue are reviewed. To address gaps in the SLE literature, the experience of each fatigue biomarker in other diseases is examined. Finally, biomarker associations with SLE pathogenesis and disease activity are discussed, as further rationale for investigation among SLE patients.

KW - Adipokines

KW - Biomarkers

KW - Fatigue

KW - Glutathione

KW - Iron deficiency

KW - Systemic lupus erythematosus

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=85027859846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027859846&partnerID=8YFLogxK

U2 - 10.2174/1573397112666161029224953

DO - 10.2174/1573397112666161029224953

M3 - Review article

VL - 13

SP - 103

EP - 112

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 2

ER -